Distigmine
Clinical data | |
---|---|
Routes of administration | By mouth, i.m. |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 4.65% [1] |
Elimination half-life | 65 h [1] |
Excretion | renal [1] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.036.360 |
Chemical and physical data | |
Formula | C22H32Br2N4O4 |
Molar mass | 576.330 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) |
Distigmine (as distigmine bromide) is a parasympathomimetic. Distigmine is similar to pyridostigmine and neostigmine but has a longer duration of action. It is available as tablets on prescription only. It is commonly used to treat various conditions, including myasthenia gravis and underactive bladder.[2] Distigmine has a greater risk of causing cholinergic crisis because of accumulation of the drug being more likely than with neostigmine or pyridostigmine and so distigmine is rarely used as a treatment for myasthenia gravis, unlike pyridostigmine and neostigmine.
References[]
- ^ a b c "Distigmine" (PDF). The Japanese Pharmacopoeia. Official Monographs (14/I ed.). Tokyo: Yakuji Nippo. Ltd. 2001. p. 599. ISBN 978-4-8408-0672-5.
- ^ Moro C, Phelps C, Veer V, Clark J, Glasziou P, Tikkinen KA, Scott AM (November 2021). "The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta-analysis". Neurourology and Urodynamics. doi:10.1002/nau.24839. PMID 34816481.
Categories:
- Acetylcholinesterase inhibitors
- Biscarbamates
- Pyridinium compounds
- Bisquaternary anticholinesterases
- Aromatic carbamates
- Nervous system drug stubs